Miraculins Launches New Canadian Web Site for PreVu(R)

http://prevu.com/
WINNIPEG, MANITOBA -- (Marketwire) -- 06/06/12 -- Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces the launch of a new Canadian web site for its PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test at www.prevu.com.
The new web site has been designed to provide comprehensive information on the science of skin cholesterol, and the PreVu technology designed to measure this new biomarker for risk of coronary artery disease (CAD). The site has been divided into two separate information areas; a comprehensive scientific and medical section for Healthcare Professionals and a general overview section for Public/Consumers who may be candidates for the PreVu POC Test.
"The launch of this new web site represents a significant step in the introduction of the PreVu POC Test to both the Canadian medical community and the general public at large," said Paul Moreau, Vice President of Sales and Marketing for Miraculins Inc.
"For the first time since we acquired PreVu, we will have a centralized online platform where stakeholders will have ongoing access to product information and clinical data, and where we can continuously showcase the technology in a consistent manner."
The new PreVu web site includes:

--  extensive presentations of clinical data covering the research and
    studies that have established the strong association between elevated
    skin cholesterol levels and coronary artery disease, as measured by
    treadmill stress testing, coronary angiography, coronary calcium,
    carotid artery thickening and carotid artery plaque; 
    
    
--  detailed technical information about the PreVu POC Test and technology
    components, including the PreVu Handheld Spectrophotometer and the PreVu
    Test Reagent Kit; 
    
    
--  comprehensive step-by-step walk-throughs of how the PreVu POC Test is
    conducted, including video presentations; 
    
    
--  a specialized self-study and proficiency qualification system for PreVu
    Test Operators across the country, facilitating streamlined clinical
    training; and 
    
    
--  clear directions for PreVu product ordering and accessing PreVu Customer
    Service and Support.

The new web site has been specifically designed for the English Canadian marketplace, with a mirror site in the French language currently under development. Similarly, web sites for additional markets such as the U.S. and European Union are under development and will reflect differences in language and presentation, given that indications for use vary across regulatory jurisdictions.
About the PreVu Non-Invasive Skin Cholesterol Test
Skin cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and has been shown in clinical trials to be strongly associated with significant CAD as measured by treadmill stress testing, coronary angiography, coronary calcium, carotid artery thickening and carotid artery plaque. The PreVu POC Test is completely painless, non-invasive, involves no blood draw or needles, requires no overnight fasting and involves no handling of potentially hazardous biomaterials. It has been developed to provide new and additive information about CAD risk that is independent of traditional risk factors, such as blood cholesterol, to help physicians more effectively assess their patients' risk. The test is conducted on the palm of the hand in less than 5 minutes with results being immediately available.
About Miraculins Inc.
Miraculins is a medical diagnostic development company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. The Company's business model is centered on acquiring, developing and commercializing diagnostic tests and risk assessment technologies in areas where there are unmet clinical needs. Once Miraculins has acquired or advanced its technology through the development stages, the Company leverages partnerships with large diagnostic companies, reference laboratories and distribution partners for final commercialization and marketing of its technologies. Of greatest interest to the Company, are diagnostic and risk assessment technologies after the completion of discovery stage research and biomarker identification, thereby requiring additional expertise and resources for development into commercialized assays. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's Management team and Board of Directors have a valuable mix of industry, business development, operations, fund raising and scientific/corporate development experience.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.
PreVu® is a registered trademark of Miraculins Inc. All Rights Reserved. 2012.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Miraculins Inc.
Christopher J. Moreau
President and CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com